Benitec Biopharma (BNTC) Proxy Filing summary

Executive summary

• Special Meeting will be held virtually to increase accessibility for all stockholders.

• Stockholders will vote on three key proposals: potential issuance of shares upon warrant exercise, amendment to the 2020 Equity and Incentive Compensation Plan, and possible adjournment to solicit more votes if needed.

• Voting is available online, by phone, or by mail, and all shares as of the record date are eligible to vote.

Voting matters and shareholder proposals

• Proposal 1 seeks approval for potential issuance of shares upon exercise of certain warrants, as required by Nasdaq Listing Rule 5635(b), to avoid a change of control without stockholder consent.

• Proposal 2 requests approval to amend the 2020 Equity and Incentive Compensation Plan, increasing the share reserve by 7,000,000 shares to a total of 8,204,537 shares.

• Proposal 3 allows adjournment of the meeting to solicit additional proxies if there are insufficient votes for Proposals 1 or 2.

• All proposals require a majority of shares present or represented by proxy to pass; abstentions count as votes against, broker non-votes have no effect.

Board of directors and corporate governance

• Board recommended voting in favor of all three proposals.

• Kishen Mehta was appointed to the Board following a Board Designation Side Letter with Suvretta Capital.

• The Board and Compensation Committee actively manage equity plan resources to balance dilution and talent retention.